CLINICAL TRIALS PROFILE FOR ASPARAGINASE

All Clinical Trials for asparaginase

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002471 ↗	Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma	Completed	Memorial Sloan Kettering Cancer Center	Phase 2	1990-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have acute B-lymphoblastic leukemia or recurrent non-Hodgkin's lymphoma.
NCT00002499 ↗	Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia	Unknown status	Grupo Argentino de Tratamiento de la Leucemia Aguda	Phase 2/Phase 3	1990-01-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II/III trial to study the effectiveness of combination chemotherapy in treating children with relapsed acute lymphocytic leukemia.
NCT00002514 ↗	Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission	Completed	Medical Research Council	Phase 3	1993-04-01	RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002514 ↗	Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission	Completed	National Cancer Institute (NCI)	Phase 3	1993-04-01	RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002514 ↗	Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission	Completed	Eastern Cooperative Oncology Group	Phase 3	1993-04-01	RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002531 ↗	Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia	Unknown status	Johann Wolfgang Goethe University Hospital	Phase 2	1993-01-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Randomized phase II trial to study the effectiveness of various combination chemotherapy regimens in treating patients with acute lymphocytic leukemia.

Clinical Trial Conditions for asparaginase

Condition Name

Condition Name for asparaginase
Intervention	Trials
Acute Lymphoblastic Leukemia	56
Leukemia	54
Lymphoma	16
Lymphoblastic Lymphoma	15

Condition MeSH

Condition MeSH for asparaginase
Intervention	Trials
Leukemia	171
Precursor Cell Lymphoblastic Leukemia-Lymphoma	169
Leukemia, Lymphoid	154
Lymphoma	63

Clinical Trial Locations for asparaginase

Trials by Country

Trials by Country for asparaginase
Location	Trials
Canada	200
Australia	83
China	51
France	37
Spain	25

Trials by US State

Trials by US State for asparaginase
Location	Trials
California	69
New York	65
Tennessee	61
Texas	60
Illinois	58

Clinical Trial Progress for asparaginase

Clinical Trial Phase

Clinical Trial Phase for asparaginase
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	7
PHASE1	2

Clinical Trial Status

Clinical Trial Status for asparaginase
Clinical Trial Phase	Trials
Completed	108
Recruiting	38
Unknown status	29

Clinical Trial Sponsors for asparaginase

Sponsor Name

Sponsor Name for asparaginase
Sponsor	Trials
National Cancer Institute (NCI)	66
Children's Oncology Group	31
St. Jude Children's Research Hospital	16

Sponsor Type

Sponsor Type for asparaginase
Sponsor	Trials
Other	332
NIH	69
Industry	66

Last updated: July 29, 2026

Asparaginase Clinical Trials Update, Market Analysis, and Market Projection (2025-2035)

Executive summary: Asparaginase is a cornerstone enzyme for acute lymphoblastic leukemia (ALL) treatment, used as either native Escherichia coli asparaginase (PEG-asparaginase alternatives exist) or pegylated formulations and related enzyme systems designed to improve pharmacokinetics and reduce immunogenicity. The near- to mid-term market is shaped by (1) pediatric ALL protocol cycles and regimen intensity, (2) uptake in consolidation and re-induction phases, (3) biosupply and shortage dynamics for specific manufacturers, (4) competitive positioning versus Erwinia-derived asparaginase when E. coli product hypersensitivity occurs, and (5) the pace of new entrants targeting longer half-life, lower immunogenicity, and improved tolerability.

No complete, drug-specific dataset (trial registry status by molecule, current FDA/EMA approvals by brand and formulation, and quantified sales/revenue history tied to each asparaginase product and geography) is provided in the prompt. Without those factual inputs, a complete and accurate clinical trials update and market projection cannot be produced.